<DOC>
	<DOCNO>NCT01850030</DOCNO>
	<brief_summary>Female inability conceive child . The purpose randomized , two-arm double-blind study demonstrate treatment daily dose 3x10mg dydrogesterone orally effective safe daily dose 3x200 mg micronized progesterone capsule administer intravaginally luteal support patient undergo IVF . The treatment start day oocyte retrieval continue pregnancy negative week 12 gestation.Patients follow treatment 30 day delivery record safety tolerability data patient newborn ( ) .</brief_summary>
	<brief_title>A Multicenter Study Comparing Efficacy , Safety Tolerability Oral Dydrogesterone 30 mg Daily Versus Intravaginal Micronized Progesterone Capsules 600 mg Daily Luteal Support In-Vitro Fertilization</brief_title>
	<detailed_description />
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Infertility , Female</mesh_term>
	<mesh_term>Dydrogesterone</mesh_term>
	<mesh_term>Progesterone</mesh_term>
	<criteria>Signed informed consent Premenopausal females , age &gt; 18 year &lt; 42 year Nonsmokers . For female past smoker , must stop tobacco usage least 3 month prior baseline visit Early follicular phase ( Day 24 ) Follicle stimulate hormone ( FSH ) less equal 15 IU/L estradiol ( E2 ) within normal limit Luteinizing hormone ( LH ) , prolactin ( PRL ) , T ( testosterone ) thyroidstimulating hormone ( TSH ) , within normal limit clinical laboratory , consider clinically significant Investigator within 6 month prior screen Documented history infertility ( e.g. , unable conceive least one year 6 month woman ≥ 38 year age bilateral tubal occlusion absence ) Normal transvaginal ultrasound screening ( within 14 day screen ) without evidence clinically significant abnormality consistent find adequate ART respect uterus adnexa ( hydrosalpinx clinically relevant uterine fibroid ) Negative pregnancy test day pituitary regulation ( prior administration gonadotropin release hormone ( GnRH ) agonist GnRH antagonist ) Clinically indicate protocol induction IVF fresh embryo Single dual embryo transfer BMI ≥ 18 ≤ 30 kg/m2 Evidence cardiovascular , respiratory , urogenital , gastrointestinal/hepatic , hematologic/immunologic , head , ears , eye , nose , throat ( HEENT ) , dermatologic/connective tissue , musculoskeletal , metabolic/nutritional , endocrine , neurologic/psychiatric , allergy , recent major surgery ( &lt; 3 month ) , relevant disease reveal history , physical examination and/or laboratory assessment could limit participation completion study Acute urogenital disease Known allergic reaction progesterone product Known allergic reaction peanuts peanut oil Intake experimental drug participation clinical trial within 30 day prior study start Mental disability lack fitness , Investigator 's opinion , preclude subject participate complete study Current recent substance abuse , include alcohol tobacco ( Note : Patients stop tobacco usage least 3 month prior screen visit would allow ) History chemotherapy radiotherapy Patients 3 unsuccessful IVF attempt Contraindication pregnancy Refusal inability comply requirement study protocol reason , include schedule clinic visit laboratory test History recurrent pregnancy loss define 3 spontaneous miscarriage</criteria>
	<gender>Female</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>41 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>